Ryan N Vogel1, Margaret Strampe2, Oladipo E Fagbemi1, Alexis Visotcky3, Sergey Tarima3, Joseph Carroll4, Deborah M Costakos5. 1. Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin; University of Minnesota Medical School, Minneapolis, Minnesota. 3. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin. 5. Department of Ophthalmology & Visual Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: dcostakos@mcw.edu.
Abstract
PURPOSE: To characterize and quantify early foveal development in preterm infants and to compare this development between eyes treated with intravitreal bevacizumab or laser photocoagulation (LPC) and untreated eyes. DESIGN: Observational case series. PARTICIPANTS: One hundred thirty-one preterm infants undergoing retinopathy of prematurity (ROP) screenings. METHODS: Handheld OCT imaging was performed longitudinally on all patients. Thickness measurements of the inner and outer retinal layers were obtained at the foveal center and the nasal and temporal foveal rims. Comparisons between treated and untreated eyes were adjusted for age and other confounding variables. MAIN OUTCOME MEASURES: Weekly change in inner and outer retinal thickness and presence of inner retinal layers, ellipsoid zone (EZ), and cystoid macular changes (CMCs). RESULTS: Outer retinal thickness at the foveal center increased by 3.1 μm/week in untreated eyes and 7.2 μm/week in bevacizumab-treated eyes (P = 0.038). Eyes treated with LPC had a lower probability of having all inner retinal layers present at the foveal center (odds ratio, 0.04; P = 0.001) and a lower probability of having the EZ present at the foveal center (odds ratio, 0.07; P = 0.024) compared with untreated eyes. Cystoid macular changes were found in 53% of patients and 22% of imaging sessions. The age-adjusted incidence of CMCs was not correlated with bevacizumab or LPC treatment. CONCLUSIONS: Intravitreal bevacizumab therapy for ROP is associated with more rapid outer retinal thickening at the foveal center, whereas LPC is associated with earlier extrusion of the inner retinal layers and delayed development of the EZ at the foveal center. Long-term follow-up is needed to determine the visual significance of these findings.
PURPOSE: To characterize and quantify early foveal development in preterm infants and to compare this development between eyes treated with intravitreal bevacizumab or laser photocoagulation (LPC) and untreated eyes. DESIGN: Observational case series. PARTICIPANTS: One hundred thirty-one preterm infants undergoing retinopathy of prematurity (ROP) screenings. METHODS: Handheld OCT imaging was performed longitudinally on all patients. Thickness measurements of the inner and outer retinal layers were obtained at the foveal center and the nasal and temporal foveal rims. Comparisons between treated and untreated eyes were adjusted for age and other confounding variables. MAIN OUTCOME MEASURES: Weekly change in inner and outer retinal thickness and presence of inner retinal layers, ellipsoid zone (EZ), and cystoid macular changes (CMCs). RESULTS: Outer retinal thickness at the foveal center increased by 3.1 μm/week in untreated eyes and 7.2 μm/week in bevacizumab-treated eyes (P = 0.038). Eyes treated with LPC had a lower probability of having all inner retinal layers present at the foveal center (odds ratio, 0.04; P = 0.001) and a lower probability of having the EZ present at the foveal center (odds ratio, 0.07; P = 0.024) compared with untreated eyes. Cystoid macular changes were found in 53% of patients and 22% of imaging sessions. The age-adjusted incidence of CMCs was not correlated with bevacizumab or LPC treatment. CONCLUSIONS: Intravitreal bevacizumab therapy for ROP is associated with more rapid outer retinal thickening at the foveal center, whereas LPC is associated with earlier extrusion of the inner retinal layers and delayed development of the EZ at the foveal center. Long-term follow-up is needed to determine the visual significance of these findings.
Authors: Chang Dai; Prabuddha Waduge; Liyang Ji; Chengchi Huang; Ye He; Hong Tian; Elizabeth Zuniga-Sanchez; Amit Bhatt; Iok-Hou Pang; Guanfang Su; Keith A Webster; Wei Li Journal: Cell Mol Life Sci Date: 2022-01-10 Impact factor: 9.261
Authors: Nikisha Kothari; Alison Chu; Jason Mingyi Huang; Fei Lin; Benjamin Ray Lin; Niranjan Manoharan; Wei Gui; Alex S Huang; Irena Tsui Journal: Am J Ophthalmol Case Rep Date: 2020-02-24